The atorvastatin effects on the prevention of contrast-induced acute kidney injury during computed tomography with contrast media
AIM: To assess the role of atorvastatin to the frequency of contrast-induced acute kidney injury (CI-AKI) in patients with cardiovascular diseases (CVD) undergoing computed tomography (CT) with intravenous contrast media.
MATERIALS AND METHODS: One hundred patients with CVD undergoing CT with with intravenous contrast media administration were included in prospective observational study (ClinicalTrials.gov ID NCT04666389). Patients were divided into 3 groups 16 (15.8%) patients receiving atorvastatin at a dose of 80 mg 24 hours and 40 mg before the CT and 40 mg after; 33 (32.7%) patients 40 mg before the CT and 40 mg after; 52 (51.5%) people not receiving statin therapy. The primary endpoint was CI-AKI according to KDIGO criteria: the 25% rise (or 0.5 mg/dl) of serum creatinine from baseline assessed 4872 hours after administration of contrast media. There were 51% of men. The average age was 59.7714.4. The most frequent cardiovascular disease was hypertension 86%.
RESULTS: CI-AKI was diagnosed in 4 (3.96%) patients. At the same time, it was not possible to establish statistically significant relationships (p0.05) between risk factors and the development of CI-AKI. Statins can be a successful way to prevent this complication.
CONCLUSION: Cardiovascular diseases may increase the risk of CI-AKI after computed tomography with intravenous contrast media administration. Therefore, it is recommended to evaluate the serum creatinine concentration in such patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
Terapevticheskii arkhiv - 94(2022), 9 vom: 24. Okt., Seite 1057-1061 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Vasin, A A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.10.2022 Date Revised 28.10.2022 published: Electronic ClinicalTrials.gov: NCT04666389 Citation Status MEDLINE |
|---|
| doi: |
10.26442/0403660.2022.09.201845 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348012616 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348012616 | ||
| 003 | DE-627 | ||
| 005 | 20231226035202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/0403660.2022.09.201845 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM348012616 | ||
| 035 | |a (NLM)36286755 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Vasin, A A |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The atorvastatin effects on the prevention of contrast-induced acute kidney injury during computed tomography with contrast media |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2022 | ||
| 500 | |a Date Revised 28.10.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04666389 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To assess the role of atorvastatin to the frequency of contrast-induced acute kidney injury (CI-AKI) in patients with cardiovascular diseases (CVD) undergoing computed tomography (CT) with intravenous contrast media | ||
| 520 | |a MATERIALS AND METHODS: One hundred patients with CVD undergoing CT with with intravenous contrast media administration were included in prospective observational study (ClinicalTrials.gov ID NCT04666389). Patients were divided into 3 groups 16 (15.8%) patients receiving atorvastatin at a dose of 80 mg 24 hours and 40 mg before the CT and 40 mg after; 33 (32.7%) patients 40 mg before the CT and 40 mg after; 52 (51.5%) people not receiving statin therapy. The primary endpoint was CI-AKI according to KDIGO criteria: the 25% rise (or 0.5 mg/dl) of serum creatinine from baseline assessed 4872 hours after administration of contrast media. There were 51% of men. The average age was 59.7714.4. The most frequent cardiovascular disease was hypertension 86% | ||
| 520 | |a RESULTS: CI-AKI was diagnosed in 4 (3.96%) patients. At the same time, it was not possible to establish statistically significant relationships (p0.05) between risk factors and the development of CI-AKI. Statins can be a successful way to prevent this complication | ||
| 520 | |a CONCLUSION: Cardiovascular diseases may increase the risk of CI-AKI after computed tomography with intravenous contrast media administration. Therefore, it is recommended to evaluate the serum creatinine concentration in such patients | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a computed tomography | |
| 650 | 4 | |a contrast media | |
| 650 | 4 | |a contrast-associated acute kidney injury | |
| 650 | 4 | |a contrast-induced acute kidney injury | |
| 650 | 4 | |a contrast-induced nephropathy | |
| 650 | 7 | |a Atorvastatin |2 NLM | |
| 650 | 7 | |a A0JWA85V8F |2 NLM | |
| 650 | 7 | |a Contrast Media |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Creatinine |2 NLM | |
| 650 | 7 | |a AYI8EX34EU |2 NLM | |
| 700 | 1 | |a Mironova, O I |e verfasserin |4 aut | |
| 700 | 1 | |a Fomin, V V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Terapevticheskii arkhiv |d 1949 |g 94(2022), 9 vom: 24. Okt., Seite 1057-1061 |w (DE-627)NLM000055425 |x 0040-3660 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2022 |g number:9 |g day:24 |g month:10 |g pages:1057-1061 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26442/0403660.2022.09.201845 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2022 |e 9 |b 24 |c 10 |h 1057-1061 | ||